- Home
- GALT vs IDYA Comparison
GALT vs IDYA Comparison
Compare GALT & IDYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GALT
- IDYA
- Stock Information
- Founded
- GALT 2000
- IDYA 2015
- Country
- GALT United States
- IDYA United States
- Employees
- GALT N/A
- IDYA N/A
- Industry
- GALT Biotechnology: Pharmaceutical Preparations
- IDYA Biotechnology: Pharmaceutical Preparations
- Sector
- GALT Health Care
- IDYA Health Care
- Exchange
- GALT Nasdaq
- IDYA Nasdaq
- Market Cap
- GALT 83.5M
- IDYA 1.9B
- IPO Year
- GALT N/A
- IDYA 2019
- Fundamental
- Price
- GALT $2.45
- IDYA $21.23
- Analyst Decision
- GALT Buy
- IDYA Strong Buy
- Analyst Count
- GALT 2
- IDYA 13
- Target Price
- GALT $6.00
- IDYA $53.42
- AVG Volume (30 Days)
- GALT 1.4M
- IDYA 1.1M
- Earning Date
- GALT 08-12-2025
- IDYA 08-05-2025
- Dividend Yield
- GALT N/A
- IDYA N/A
- EPS Growth
- GALT N/A
- IDYA N/A
- EPS
- GALT N/A
- IDYA N/A
- Revenue
- GALT N/A
- IDYA $7,000,000.00
- Revenue This Year
- GALT N/A
- IDYA $101.20
- Revenue Next Year
- GALT N/A
- IDYA $286.70
- P/E Ratio
- GALT N/A
- IDYA N/A
- Revenue Growth
- GALT N/A
- IDYA N/A
- 52 Week Low
- GALT $0.73
- IDYA $13.45
- 52 Week High
- GALT $3.90
- IDYA $44.42
- Technical
- Relative Strength Index (RSI)
- GALT 61.39
- IDYA 62.23
- Support Level
- GALT $2.21
- IDYA $21.08
- Resistance Level
- GALT $3.90
- IDYA $22.37
- Average True Range (ATR)
- GALT 0.47
- IDYA 0.92
- MACD
- GALT 0.09
- IDYA -0.09
- Stochastic Oscillator
- GALT 40.84
- IDYA 61.72
About GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
About IDYA IDEAYA Biosciences Inc.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.